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G-RC-10
MULTICENTRE PHASE II TRIAL OF TAXOTERE AND CISPLATIN IN ADVANCED NON-SMALL
CELL LUNG CANCER
James CM Ho. WK Lam, *Clara Ooi, Mary Ip, Kenneth Tsang University Departments of Medicine and
*Diagnostic Radiology, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR
Non-small cell lung cancer is the commonest cause of cancer death in Hong Kong and frequently presents
itself at advanced stages. Combination chemotherapy has been used in advanced stages with unsatisfactory
response. We have performed a phase II study on the response rate and safety profile of Taxotere and cisplatin
given in combination in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC).
Chemotherapy naive patients with histologically or cytologically proven stage III or IV unresectable NSCLC
and good performance state were recruited consecutively. Exclusion criteria included brain or leptomeningeal
involvement, major organ failure, previous malignancies, active uncontrolled infection, or definite
contraindications for the use of corticosteroids. Taxotere 75mg/m2 as 1 hour intravenous infusion and cisplatin
75mg/m2 as 30 minutes intravenous infusion were given in 3-weekly intervals for 6 cycles. Interim results
were obtained from 20 patients (10F) with age 55.8+7.34 years. There were 14 adenocarcinomas, 3 squamous
cell carcinoma and 3 undifferentiated NSCLC with 2 in TNM stage III A, 10 in stage IIIB and 8 in stage IV.
The partial response rate after 3 courses of chemotherapy was 42% and 47% had stable disease. After completion
of 6 courses of chemotherapy, the overall response rates were 53%, 26% had stable disease, and 21 % progressive
disease. Grade 3 or 4 neutropenia occurred in 55% of chemotherapy cycles in which 4 out of 20 patients
required dose reduction and 3 of them required granulocyte-colony stimulating factor support. Neutropenic
fever occurred in 17%. Grade 3 thrombocytopenia occurred in 3%. Significant toxicities (grade 3 or 4)
included nausea (1%), vomiting (10%), diarrhoea (2%), infection (3%), asthenia (2%) and allergy (1%). There
had been no treatment-related deaths. The combination of Taxotere and cisplatin appears to be a fairly well
tolerated and highly effective regime in the treatment of advanced NSCLC. Further studies are warranted to
evaluate the impact of this combination on the median term response and survival of these unfortunate patients.
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SERUM LEPTIN AND VASCULAR RISK FACTORS IN OBSTRUCTIVE SLEEP APNOEA
Mary SM Ip, Karen SL Lam, Chung-man Ho. Kenneth WT Tsang, Wah-kit Lam. University Department of
Medicine, Queen Mary Hospital, Hong Kong
Study objectives: To define the metabolic profile relevant to vascular risks in obstructive sleep apnoea (OSA)
and the role of leptin resistance in this risk profile
Design: Case control study
Setting: Sleep Laboratory, Queen Mary Hospital, University of Hong Kong
Methods: Thirty OSA subjects were compared with 30 non-OSA subjects, matched for body mass index
(BMI), age, sex and menopausal status, in the following parameters : girth of neck, waist and hip, skinfold
thickness, fasting serum levels of lipids, glucose, insulin and leptin.
Results: Compared to control subjects without OSA, despite a similar BMI, the OSA group had a significantly
more adverse vascular risk factor profile including dyslipidemia, higher diastolic blood pressure, insulin
resistance, and greater adiposity reflected by skinfold thickness. OSA subjects also had higher circulating
leptin levels (9.2±4.2 vs 6.5± 3.8 ng/ml, mean ± SD, p=0.001). Serum leptin levels correlated positively with
BMI, skinfold thickness, serum cholesterol, LDL-cholesterol, insulin, insulin:glucose ratio, apnoea-hypopnea
index and oxygen desaturation time, and multiple stepwise regression analysis identified skinfold thickness,
waist : hip ratio, serum LDL-cholesterol, and diastolic blood pressure as independent correlates, while only
serum insulin and diastolic blood pressure were independent correlates in OSA subjects. After treatment with
nCPAP for 6 months, there was a significant decrease in circulating leptin (p =0.01) and triglyceride levels
(p=0.02) without change in anthropometric and other metabolic characteristics.
Conclusion: Despite controlling for BMI, OSA subjects showed a distinct profile with clustering of vascular
risk factors. Hyperleptinaemia was present in OSA subject but it can be normalised by treatment with nCPAP,
suggesting that increased leptin resistance was not the cause of OSA or its associated vascular risks.
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